CORD-19:3c1f47a07aaf0e393dee9fbd08596a4b9f4f0a03 / 30998-31149 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T301","span":{"begin":0,"end":151},"obj":"Sentence"},{"id":"T87604","span":{"begin":0,"end":151},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Telithromycin showed a sustained activity against both SPN (99.6% susceptible, MIC50/90 0.015/0.25 mg/L) and HI (99.3% susceptible, MIC50/90 1/2 mg/L)."}

{"project":"CORD-PICO","denotations":[{"id":"p1_all129","span":{"begin":0,"end":13},"obj":"Intervention"},{"id":"p1_all130","span":{"begin":23,"end":41},"obj":"Outcome"}],"text":"Telithromycin showed a sustained activity against both SPN (99.6% susceptible, MIC50/90 0.015/0.25 mg/L) and HI (99.3% susceptible, MIC50/90 1/2 mg/L)."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T301","span":{"begin":0,"end":151},"obj":"Sentence"}],"text":"Telithromycin showed a sustained activity against both SPN (99.6% susceptible, MIC50/90 0.015/0.25 mg/L) and HI (99.3% susceptible, MIC50/90 1/2 mg/L)."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T106","span":{"begin":55,"end":58},"obj":"Disease"},{"id":"T99853","span":{"begin":55,"end":58},"obj":"Disease"}],"attributes":[{"id":"A106","pred":"mondo_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/MONDO_0005972"},{"id":"A81462","pred":"mondo_id","subj":"T99853","obj":"http://purl.obolibrary.org/obo/MONDO_0005972"}],"text":"Telithromycin showed a sustained activity against both SPN (99.6% susceptible, MIC50/90 0.015/0.25 mg/L) and HI (99.3% susceptible, MIC50/90 1/2 mg/L)."}